Catherine Pellat-Deceunynck

8PUBLICATIONS
27CO-AUTHORS
Medical biotechnology not elsewhere classifiedHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Biomaterials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 02, 2026
Venetoclax in myeloma: t(11;14) and what else?

Catherine Pellat-Deceunynck

|Feb 19, 2026
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

Candice Madiot, Céline Bellanger, Christelle Dousset

|Feb 06, 2025
VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.

Ophélie Champion, Sophie Maïga, Chloé Antier

|Oct 09, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Romane Durand, Céline Bellanger, Géraldine Descamps

|Sep 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret

|Mar 06, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

C Grandclément, C Estoppey, E Dheilly

Pageof 2

Frequent Collaborators

5 joint publications

David Chiron

3 joint publications

Géraldine Descamps

3 joint publications

Patricia Gomez-Bougie

3 joint publications

Yannick Le Bris